AnaptysBio Inc (ANAB)

AnaptysBio Inc (ANAB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.5B; returns 1 day +1.3%, 1 week +4.5%, 1 year +115.0%.

AnaptysBio Inc. (ANAB) is a clinical-stage biotechnology company primarily focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. Its business model combines a proprietary pipeline of wholly-owned drug candidates with a significant revenue stream derived from out-licensed therapeutic antibodies through financial collaborations.

Groups ANAB belongs to

• Shrinking Share Count
• Biotechnology
• Buying Back Stock
• Recent Forward Splits
• Clinical Stage Biopharma
• Autoimmune Diseases
• Royalty Streams
• Healthcare
• Clinical Stage
• Biopharmaceutical
• Chronic Inflammatory Diseases
• Oncology
• Monoclonal Antibodies

ANAB financial model: income statement, cash flow and balance sheet